Skip to content

Opko Health OPK Additional Paid-In Capital

Additional Paid-In Capital at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
$2.35B+1.6%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
$1.13B+33.4%
HRO
HarrowHROW
$212.8M-5.7%
Precigen logo
PrecigenPGEN
$2.37B+11.2%
Immunome logo
ImmunomeIMNM
$1.37B+58.5%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$4.48B+5.4%

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B-22.4%
P/S1.9×-0.2×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's additional paid-in capital?
Opko Health (OPK) reported additional paid-in capital of $3.57B in Q1 2026.
How has Opko Health's additional paid-in capital changed year-over-year?
Opko Health's additional paid-in capital increased by 2.5% year-over-year, from $3.48B to $3.57B.
What is the long-term trend for Opko Health's additional paid-in capital?
Over 5 years (2020 to 2025), Opko Health's additional paid-in capital has grown at a 2.5% compound annual growth rate (CAGR), from $3.15B to $3.57B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.